A PHARMO Study on the Utilization of Pioglitazone in Clinical Practice in The Netherlands with Regard to Diabetic Treatment Regimen and Co-morbidities First published 21/07/2015 Last updated 01/04/2024 EU PAS number:EUPAS10001 Study Finalised
The PHARMO Institute for Drug Outcomes Research (PHARMO Institute) Netherlands First published:07/01/2022 Last updated 24/07/2024 Institution Laboratory/Research/Testing facility ENCePP partner